Chitosan oligosaccharide mitigates kidney injury in prediabetic rats by improving intestinal barrier and renal autophagy

Carbohydr Polym. 2022 Jul 15:288:119405. doi: 10.1016/j.carbpol.2022.119405. Epub 2022 Mar 24.

Abstract

Consumption of a high-fat diet (HFD) not only increases the risk of metabolic syndrome but also initiates kidney injury. Lipid accumulation-induced systemic low-grade inflammation is an upstream mechanism of kidney injury associated with prediabetes. Chitosan oligosaccharide (COS) provides potent anti-obesity effects through several mechanisms including fecal lipid excretion. In this study, we investigated the effects of COS on the prevention of obesity-related complications and its ability to confer renoprotection in a prediabetic model. Rats fed on a HFD developed obesity, glucose intolerance and kidney dysfunction. COS intervention successfully ameliorated these conditions (p < 0.05) by attenuating intestinal lipid absorption and the renal inflammation-autophagy-apoptosis axis. A novel anti-inflammatory effect of COS had been demonstrated by the strengthening of intestinal barrier integrity via calcium-sensing receptor (p < 0.05). The use of COS as a supplement may be useful in reducing prediabetic complications especially renal injury and the risk of type 2 diabetes.

Keywords: Chitosan oligosaccharide; Intestinal barrier; Intestinal lipid absorption; Kidney injury; Obesity; Prediabetes.

MeSH terms

  • Animals
  • Autophagy
  • Chitosan* / metabolism
  • Chitosan* / pharmacology
  • Chitosan* / therapeutic use
  • Diabetes Mellitus, Type 2* / metabolism
  • Diet, High-Fat
  • Inflammation / metabolism
  • Kidney
  • Lipids
  • Obesity / metabolism
  • Oligosaccharides / metabolism
  • Oligosaccharides / pharmacology
  • Oligosaccharides / therapeutic use
  • Prediabetic State* / complications
  • Prediabetic State* / drug therapy
  • Prediabetic State* / metabolism
  • Rats

Substances

  • Lipids
  • Oligosaccharides
  • Chitosan